Netherlands-based drug-delivery specialist OctoPlus will perform formulation development and clinical manufacturing for an unnamed mid-sized European drug maker. The work encompasses three products, now in Phase I to Phase III clinical development.
The contract "significantly contributes" to its annual revenues, the company says.
In June, OctoPlus opened and began production in a manufacturing facility in Leiden, the culmination of a 2-1/2-year effort. The facility, which is being used to produce final drug product, is approved by Dutch authorities to manufacture drugs to international GMP guidelines. The plant more than doubles OctoPlus manufacturing capacity. It also allows the company to make products covering all phases of preclinical drug development, as well as small-scale commercial supplies of injectable pharmaceutical products and other complex formulations.